Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pimicotinib - Abbisko Therapeutics

Next Previous
Drug Profile

Pimicotinib - Abbisko Therapeutics

Alternative Names: ABSK-021

Latest Information Update: 28 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbisko Therapeutics
  • Developer Abbisko Therapeutics; Sperogenix Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Macrophage colony-stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant cell tumours
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Giant cell tumour of tendon sheath
  • Phase III Solid tumours
  • Phase II Graft-versus-host disease; Pancreatic cancer
  • Preclinical Osteosarcoma
  • No development reported Amyotrophic lateral sclerosis

Most Recent Events

  • 28 Aug 2025 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in China (PO)
  • 16 Jun 2025 Abbisko Therapeutics completes a phase I bioequivalence trial (In volunteers) in China (PO, Capsule) (NCT07126249)
  • 10 Jun 2025 Merck plans to file a New Drug Application to the US Food and Drug Administration for pimicotinib in USA and other markets around the world

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top